Discover AstraZeneca PLC's latest financial insights, including voting rights and regulatory compliance under Form 20-F. Essential for investors and stakeholders.
Discover AstraZeneca's strategic shift in its listing structure, enhancing global investor access and compliance with UK governance. Key insights from the September 2025 Form 6-K.
Explore AstraZeneca PLC's latest 6-K report detailing a transaction by Non-Executive Director Karen Knudsen involving 9 ADSs. Key insights for September 2025 compliance.
AstraZeneca's Form 6-K reveals Koselugo's EU approval for inoperable plexiform neurofibromas, based on promising KOMET trial results. A significant step for NF1 patients.
Explore AstraZeneca's latest Form 6-K report detailing promising Saphnelo trial results for SLE, highlighting innovative treatment options and future regulatory steps.
Discover AstraZeneca PLC's latest Form 6-K detailing voting rights and share capital as of August 31, 2025. Key info for shareholders on compliance and transparency.
AstraZeneca PLC's August 2025 report corrects a TR-1 notification error. Shareholders should refer to the proper TR-1 from 21 August. Find details on their investor relations site.
Explore AstraZeneca's August 2025 Form 6-K detailing an insider share sale by CFO Aradhana Sarin. Key transaction insights and compliance with EU regulations included.
Discover Gilead Sciences' significant 8-K filing dated August 10, 2025. Stay informed on crucial developments impacting stock GILD and shareholder interests.
Explore AstraZeneca PLC's latest Form 6-K, filed on August 1, 2025, detailing 1.55B voting rights and compliance with UK regulations vital for shareholders.
AstraZeneca plans to invest $50B in US manufacturing and R&D by 2030, aiming for $80B revenue. This will create tens of thousands of jobs and enhance drug production capabilities.
AstraZeneca's Baxdrostat shows significant promise in treating uncontrolled hypertension, marking a major advancement in cardiovascular medicine.